| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 42 | 2025 | 334 | 5.740 |
Why?
|
| Neurology | 4 | 2021 | 108 | 2.060 |
Why?
|
| Nervous System Diseases | 6 | 2021 | 370 | 1.770 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 6 | 2024 | 22 | 1.680 |
Why?
|
| Neuromyelitis Optica | 7 | 2023 | 31 | 1.230 |
Why?
|
| Muscular Atrophy, Spinal | 3 | 2022 | 43 | 1.000 |
Why?
|
| Pediatrics | 5 | 2021 | 1139 | 0.950 |
Why?
|
| Child | 74 | 2025 | 24144 | 0.950 |
Why?
|
| Disease Progression | 11 | 2025 | 2027 | 0.880 |
Why?
|
| Adolescent | 54 | 2025 | 19030 | 0.840 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 3 | 2024 | 8 | 0.800 |
Why?
|
| Recurrence | 11 | 2025 | 1419 | 0.780 |
Why?
|
| Biological Products | 1 | 2022 | 113 | 0.710 |
Why?
|
| Neuromuscular Diseases | 1 | 2020 | 54 | 0.700 |
Why?
|
| Hypoglossal Nerve Diseases | 1 | 2019 | 3 | 0.670 |
Why?
|
| Humans | 109 | 2025 | 122991 | 0.670 |
Why?
|
| Myelitis, Transverse | 4 | 2016 | 6 | 0.650 |
Why?
|
| HLA-DRB1 Chains | 6 | 2024 | 39 | 0.650 |
Why?
|
| Meningitis | 1 | 2019 | 99 | 0.640 |
Why?
|
| Child, Preschool | 37 | 2025 | 13819 | 0.630 |
Why?
|
| Headache | 1 | 2019 | 107 | 0.630 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2023 | 3090 | 0.600 |
Why?
|
| Rituximab | 4 | 2024 | 156 | 0.600 |
Why?
|
| Disabled Children | 1 | 2018 | 25 | 0.590 |
Why?
|
| Male | 72 | 2025 | 59898 | 0.590 |
Why?
|
| Neurodevelopmental Disorders | 2 | 2021 | 469 | 0.580 |
Why?
|
| Magnetic Resonance Imaging | 17 | 2025 | 3510 | 0.580 |
Why?
|
| Hypertrophy | 2 | 2019 | 100 | 0.560 |
Why?
|
| Age of Onset | 10 | 2025 | 581 | 0.560 |
Why?
|
| Plasma Exchange | 1 | 2018 | 83 | 0.560 |
Why?
|
| Fatigue | 1 | 2018 | 217 | 0.540 |
Why?
|
| Internship and Residency | 3 | 2021 | 1158 | 0.540 |
Why?
|
| Female | 67 | 2025 | 65304 | 0.530 |
Why?
|
| RNA-Binding Protein FUS | 1 | 2016 | 13 | 0.530 |
Why?
|
| Motor Neuron Disease | 1 | 2016 | 15 | 0.530 |
Why?
|
| Immunosuppressive Agents | 6 | 2024 | 645 | 0.530 |
Why?
|
| Cerebellar Ataxia | 3 | 2023 | 65 | 0.520 |
Why?
|
| Muscular Dystrophies | 3 | 2023 | 52 | 0.510 |
Why?
|
| Telemedicine | 1 | 2021 | 421 | 0.500 |
Why?
|
| Gene-Environment Interaction | 4 | 2023 | 120 | 0.490 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 864 | 0.480 |
Why?
|
| Pituitary Diseases | 1 | 2014 | 10 | 0.470 |
Why?
|
| Lymphocytosis | 1 | 2014 | 14 | 0.470 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 510 | 0.460 |
Why?
|
| Infant | 23 | 2024 | 12286 | 0.450 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 5 | 2024 | 29 | 0.450 |
Why?
|
| Opsoclonus-Myoclonus Syndrome | 2 | 2023 | 2 | 0.420 |
Why?
|
| Immunologic Factors | 4 | 2024 | 179 | 0.420 |
Why?
|
| Phosphotransferases (Phosphomutases) | 1 | 2012 | 4 | 0.420 |
Why?
|
| Muscular Dystrophy, Duchenne | 3 | 2022 | 63 | 0.410 |
Why?
|
| Demyelinating Diseases | 3 | 2023 | 67 | 0.410 |
Why?
|
| Leukodystrophy, Globoid Cell | 1 | 2012 | 4 | 0.410 |
Why?
|
| Mutation | 13 | 2024 | 5772 | 0.410 |
Why?
|
| Phaeohyphomycosis | 2 | 2022 | 11 | 0.400 |
Why?
|
| Encephalitis | 3 | 2023 | 108 | 0.400 |
Why?
|
| Congenital Disorders of Glycosylation | 1 | 2012 | 38 | 0.400 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 2 | 2023 | 23 | 0.400 |
Why?
|
| Exome | 2 | 2016 | 1041 | 0.390 |
Why?
|
| Quality of Life | 2 | 2018 | 1926 | 0.370 |
Why?
|
| Optic Nerve Diseases | 1 | 2012 | 88 | 0.360 |
Why?
|
| Oligonucleotides | 2 | 2022 | 88 | 0.350 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2024 | 285 | 0.350 |
Why?
|
| Muscle Weakness | 4 | 2022 | 83 | 0.340 |
Why?
|
| Brain Diseases | 2 | 2023 | 294 | 0.330 |
Why?
|
| Alleles | 6 | 2024 | 1602 | 0.330 |
Why?
|
| Autoantibodies | 7 | 2024 | 422 | 0.320 |
Why?
|
| Case-Control Studies | 12 | 2024 | 3259 | 0.310 |
Why?
|
| Developmental Disabilities | 3 | 2024 | 695 | 0.300 |
Why?
|
| Cognitive Dysfunction | 2 | 2022 | 222 | 0.290 |
Why?
|
| Fingolimod Hydrochloride | 2 | 2024 | 32 | 0.280 |
Why?
|
| Retrospective Studies | 16 | 2025 | 15928 | 0.280 |
Why?
|
| Cognition Disorders | 2 | 2022 | 555 | 0.280 |
Why?
|
| Diagnosis, Differential | 9 | 2021 | 1870 | 0.280 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 2 | 2017 | 32 | 0.270 |
Why?
|
| Vitamin D | 2 | 2019 | 159 | 0.270 |
Why?
|
| Neurodegenerative Diseases | 2 | 2021 | 253 | 0.270 |
Why?
|
| Movement Disorders | 2 | 2014 | 221 | 0.270 |
Why?
|
| Infant, Newborn | 7 | 2022 | 8068 | 0.270 |
Why?
|
| Cohort Studies | 9 | 2025 | 4704 | 0.260 |
Why?
|
| Intellectual Disability | 3 | 2023 | 1043 | 0.260 |
Why?
|
| Environmental Exposure | 2 | 2018 | 218 | 0.250 |
Why?
|
| Autoimmune Diseases of the Nervous System | 2 | 2023 | 30 | 0.250 |
Why?
|
| Young Adult | 14 | 2024 | 8840 | 0.250 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 2837 | 0.250 |
Why?
|
| Sunlight | 1 | 2025 | 23 | 0.250 |
Why?
|
| Menarche | 1 | 2025 | 33 | 0.240 |
Why?
|
| Neurofilament Proteins | 1 | 2025 | 27 | 0.240 |
Why?
|
| Mitochondrial Myopathies | 2 | 2020 | 28 | 0.240 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2007 | 215 | 0.240 |
Why?
|
| Aquaporin 4 | 4 | 2023 | 15 | 0.240 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 2 | 2023 | 98 | 0.230 |
Why?
|
| Diskectomy | 1 | 2024 | 9 | 0.230 |
Why?
|
| Diet | 2 | 2024 | 1125 | 0.230 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2022 | 171 | 0.230 |
Why?
|
| Phenotype | 10 | 2024 | 4221 | 0.230 |
Why?
|
| Isoxazoles | 1 | 2004 | 31 | 0.230 |
Why?
|
| Myoclonic Epilepsies, Progressive | 1 | 2023 | 13 | 0.220 |
Why?
|
| United States | 13 | 2024 | 10595 | 0.220 |
Why?
|
| Myoclonus | 1 | 2023 | 32 | 0.220 |
Why?
|
| Cerebral Palsy | 1 | 2005 | 79 | 0.220 |
Why?
|
| Kinesis | 1 | 2003 | 2 | 0.220 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2005 | 167 | 0.220 |
Why?
|
| Membrane Transport Proteins | 1 | 2024 | 177 | 0.220 |
Why?
|
| Cervical Vertebrae | 1 | 2024 | 107 | 0.210 |
Why?
|
| Risk Factors | 13 | 2024 | 9974 | 0.210 |
Why?
|
| Brain | 9 | 2024 | 2943 | 0.210 |
Why?
|
| Spinal Fusion | 1 | 2024 | 107 | 0.210 |
Why?
|
| Contracture | 1 | 2022 | 24 | 0.210 |
Why?
|
| Neural Conduction | 2 | 2020 | 92 | 0.210 |
Why?
|
| Cerebral Ventriculitis | 1 | 2022 | 15 | 0.210 |
Why?
|
| Central Nervous System Infections | 1 | 2022 | 21 | 0.210 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2022 | 8 | 0.200 |
Why?
|
| Muscular Diseases | 1 | 2023 | 102 | 0.200 |
Why?
|
| Dystonic Disorders | 1 | 2023 | 81 | 0.200 |
Why?
|
| Electromyography | 2 | 2020 | 160 | 0.200 |
Why?
|
| Microcephaly | 3 | 2013 | 328 | 0.200 |
Why?
|
| B7-2 Antigen | 1 | 2022 | 16 | 0.200 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2016 | 457 | 0.200 |
Why?
|
| Eating | 1 | 2024 | 373 | 0.200 |
Why?
|
| Ozone | 1 | 2022 | 18 | 0.200 |
Why?
|
| Spasms, Infantile | 1 | 2004 | 171 | 0.200 |
Why?
|
| Gait Ataxia | 1 | 2021 | 6 | 0.190 |
Why?
|
| Ocular Motility Disorders | 1 | 2022 | 38 | 0.190 |
Why?
|
| Muscular Dystrophy, Emery-Dreifuss | 1 | 2021 | 9 | 0.190 |
Why?
|
| Membrane Proteins | 2 | 2021 | 1524 | 0.190 |
Why?
|
| Dystonia | 1 | 2023 | 169 | 0.190 |
Why?
|
| Gain of Function Mutation | 1 | 2022 | 104 | 0.190 |
Why?
|
| Diplopia | 1 | 2021 | 41 | 0.190 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2021 | 12 | 0.190 |
Why?
|
| Aniridia | 1 | 2021 | 12 | 0.190 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2021 | 25 | 0.190 |
Why?
|
| Cerebellum | 1 | 2005 | 413 | 0.190 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2021 | 35 | 0.190 |
Why?
|
| Injection Site Reaction | 1 | 2021 | 7 | 0.190 |
Why?
|
| Biopsy | 3 | 2021 | 1239 | 0.190 |
Why?
|
| Spinal Cord | 3 | 2015 | 293 | 0.180 |
Why?
|
| Myopathy, Central Core | 1 | 2020 | 5 | 0.180 |
Why?
|
| Adult | 17 | 2024 | 28978 | 0.180 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 868 | 0.180 |
Why?
|
| Scoliosis | 1 | 2022 | 134 | 0.180 |
Why?
|
| Anticonvulsants | 1 | 2004 | 370 | 0.180 |
Why?
|
| Migraine with Aura | 1 | 2021 | 16 | 0.180 |
Why?
|
| Vertebral Artery Dissection | 1 | 2000 | 4 | 0.180 |
Why?
|
| Hemiplegia | 1 | 2021 | 40 | 0.180 |
Why?
|
| Brain Abscess | 1 | 2021 | 56 | 0.180 |
Why?
|
| Neurologists | 1 | 2020 | 17 | 0.180 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2020 | 11 | 0.180 |
Why?
|
| Genetic Association Studies | 2 | 2021 | 760 | 0.180 |
Why?
|
| Treatment Outcome | 10 | 2024 | 12087 | 0.180 |
Why?
|
| Glucocorticoids | 3 | 2021 | 379 | 0.180 |
Why?
|
| Central Nervous System Diseases | 1 | 2021 | 105 | 0.180 |
Why?
|
| Myasthenia Gravis | 1 | 2021 | 71 | 0.180 |
Why?
|
| Research Design | 1 | 2024 | 688 | 0.180 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2019 | 2595 | 0.180 |
Why?
|
| Accreditation | 1 | 2020 | 82 | 0.180 |
Why?
|
| Glycine-tRNA Ligase | 1 | 2020 | 6 | 0.180 |
Why?
|
| Introns | 1 | 2021 | 302 | 0.170 |
Why?
|
| Myositis | 1 | 2020 | 51 | 0.170 |
Why?
|
| Survival of Motor Neuron 1 Protein | 1 | 2020 | 20 | 0.170 |
Why?
|
| Seizures | 4 | 2023 | 871 | 0.170 |
Why?
|
| Chromosome Deletion | 2 | 2014 | 638 | 0.170 |
Why?
|
| Hashimoto Disease | 1 | 2020 | 21 | 0.170 |
Why?
|
| Cat-Scratch Disease | 1 | 2020 | 33 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 501 | 0.170 |
Why?
|
| Microarray Analysis | 1 | 2020 | 231 | 0.170 |
Why?
|
| Immunoglobulin G | 4 | 2022 | 771 | 0.170 |
Why?
|
| Mutation, Missense | 4 | 2021 | 845 | 0.170 |
Why?
|
| Echocardiography | 2 | 2016 | 1069 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1088 | 0.170 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2020 | 30 | 0.170 |
Why?
|
| Anaphylaxis | 1 | 2021 | 77 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 149 | 0.170 |
Why?
|
| Migraine Disorders | 1 | 2000 | 64 | 0.170 |
Why?
|
| Communicable Diseases | 2 | 2020 | 163 | 0.160 |
Why?
|
| Disabled Persons | 1 | 2020 | 100 | 0.160 |
Why?
|
| Infant, Premature | 1 | 2005 | 798 | 0.160 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2022 | 769 | 0.160 |
Why?
|
| Neutropenia | 1 | 2021 | 202 | 0.160 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 300 | 0.160 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 5031 | 0.160 |
Why?
|
| Syndrome | 5 | 2023 | 1113 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 249 | 0.160 |
Why?
|
| Education, Special | 1 | 2018 | 11 | 0.160 |
Why?
|
| Long-Term Care | 1 | 2018 | 71 | 0.150 |
Why?
|
| Disease Susceptibility | 2 | 2017 | 298 | 0.150 |
Why?
|
| Family | 2 | 2021 | 576 | 0.150 |
Why?
|
| Adjuvants, Immunologic | 1 | 2020 | 376 | 0.150 |
Why?
|
| Recovery of Function | 1 | 2020 | 437 | 0.150 |
Why?
|
| West Nile Fever | 1 | 2020 | 139 | 0.150 |
Why?
|
| Rehabilitation | 1 | 2018 | 29 | 0.150 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2020 | 256 | 0.150 |
Why?
|
| Immune System Diseases | 1 | 2018 | 44 | 0.150 |
Why?
|
| Child Health Services | 1 | 2018 | 86 | 0.150 |
Why?
|
| Filamins | 1 | 2017 | 25 | 0.140 |
Why?
|
| Abnormalities, Multiple | 2 | 2014 | 964 | 0.140 |
Why?
|
| Muscle Hypotonia | 2 | 2016 | 185 | 0.140 |
Why?
|
| Ataxia | 3 | 2023 | 168 | 0.140 |
Why?
|
| Neuroblastoma | 1 | 2022 | 509 | 0.140 |
Why?
|
| Transcription Factors | 2 | 2019 | 2577 | 0.140 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 236 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 2 | 2020 | 1760 | 0.140 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 196 | 0.140 |
Why?
|
| Calcium Channels | 1 | 2017 | 160 | 0.140 |
Why?
|
| Prednisone | 2 | 2021 | 273 | 0.130 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 3 | 2015 | 11 | 0.130 |
Why?
|
| Atrophy | 2 | 2008 | 225 | 0.130 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 714 | 0.130 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2016 | 37 | 0.130 |
Why?
|
| Patient-Centered Care | 1 | 2018 | 225 | 0.130 |
Why?
|
| Dietary Fats | 1 | 2017 | 296 | 0.130 |
Why?
|
| Rhabdomyolysis | 1 | 2016 | 35 | 0.130 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2015 | 222 | 0.130 |
Why?
|
| Hydroxymethyl and Formyl Transferases | 1 | 2015 | 5 | 0.130 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 208 | 0.130 |
Why?
|
| Longitudinal Studies | 3 | 2025 | 1313 | 0.120 |
Why?
|
| Nuclear Proteins | 1 | 2021 | 1267 | 0.120 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 239 | 0.120 |
Why?
|
| B-Lymphocytes | 3 | 2023 | 518 | 0.120 |
Why?
|
| Heart Conduction System | 1 | 2016 | 145 | 0.120 |
Why?
|
| Child Day Care Centers | 1 | 2014 | 25 | 0.120 |
Why?
|
| Hypersensitivity | 1 | 2017 | 182 | 0.120 |
Why?
|
| Biomedical Research | 2 | 2024 | 519 | 0.120 |
Why?
|
| Respiratory Insufficiency | 1 | 2017 | 234 | 0.120 |
Why?
|
| Lambert-Eaton Myasthenic Syndrome | 1 | 2014 | 7 | 0.120 |
Why?
|
| Global Health | 1 | 2019 | 557 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2014 | 119 | 0.110 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2016 | 214 | 0.110 |
Why?
|
| Health Behavior | 1 | 2017 | 382 | 0.110 |
Why?
|
| Prospective Studies | 5 | 2024 | 6022 | 0.110 |
Why?
|
| Mannosyltransferases | 1 | 2013 | 2 | 0.110 |
Why?
|
| Hereditary Sensory and Motor Neuropathy | 1 | 2013 | 36 | 0.110 |
Why?
|
| Walker-Warburg Syndrome | 1 | 2013 | 5 | 0.110 |
Why?
|
| Cardiomyopathies | 2 | 2016 | 481 | 0.110 |
Why?
|
| Environment | 1 | 2014 | 143 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2020 | 978 | 0.110 |
Why?
|
| Curriculum | 1 | 2019 | 718 | 0.110 |
Why?
|
| Herpesvirus 4, Human | 3 | 2024 | 659 | 0.110 |
Why?
|
| Ultraviolet Rays | 2 | 2025 | 204 | 0.110 |
Why?
|
| Epilepsy | 1 | 2021 | 859 | 0.110 |
Why?
|
| Mitochondrial Diseases | 1 | 2015 | 135 | 0.110 |
Why?
|
| Lung Diseases | 1 | 2017 | 385 | 0.110 |
Why?
|
| Caregivers | 1 | 2018 | 564 | 0.110 |
Why?
|
| Body Mass Index | 2 | 2017 | 1542 | 0.110 |
Why?
|
| Heart Rate | 1 | 2016 | 585 | 0.110 |
Why?
|
| Lung Transplantation | 1 | 2017 | 316 | 0.110 |
Why?
|
| Breast Feeding | 1 | 2014 | 219 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2017 | 388 | 0.100 |
Why?
|
| Hospitalization | 2 | 2018 | 1732 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 710 | 0.100 |
Why?
|
| Eye | 1 | 2014 | 226 | 0.100 |
Why?
|
| Siblings | 1 | 2013 | 195 | 0.100 |
Why?
|
| Eye Movements | 1 | 2012 | 69 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2019 | 831 | 0.100 |
Why?
|
| Hypertension, Pulmonary | 1 | 2017 | 431 | 0.100 |
Why?
|
| Ascomycota | 2 | 2022 | 25 | 0.100 |
Why?
|
| DNA, Mitochondrial | 2 | 2011 | 211 | 0.100 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 366 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2012 | 100 | 0.100 |
Why?
|
| Methylprednisolone | 2 | 2008 | 90 | 0.100 |
Why?
|
| Mitochondria | 1 | 2016 | 682 | 0.100 |
Why?
|
| Optic Atrophy, Hereditary, Leber | 1 | 2011 | 14 | 0.090 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2022 | 141 | 0.090 |
Why?
|
| Leigh Disease | 1 | 2011 | 25 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 554 | 0.090 |
Why?
|
| Genome, Human | 1 | 2017 | 1266 | 0.090 |
Why?
|
| Central Nervous System | 2 | 2022 | 253 | 0.090 |
Why?
|
| Feeding Behavior | 1 | 2016 | 696 | 0.090 |
Why?
|
| Genotype | 3 | 2023 | 2546 | 0.080 |
Why?
|
| Hospitals, Pediatric | 1 | 2014 | 780 | 0.080 |
Why?
|
| Biomarkers | 4 | 2025 | 2940 | 0.080 |
Why?
|
| Homozygote | 3 | 2016 | 533 | 0.080 |
Why?
|
| Acute Disease | 1 | 2012 | 1089 | 0.080 |
Why?
|
| Comorbidity | 1 | 2014 | 1497 | 0.080 |
Why?
|
| Guanidinoacetate N-Methyltransferase | 1 | 2008 | 9 | 0.080 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2008 | 19 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 2021 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2008 | 139 | 0.080 |
Why?
|
| Axons | 2 | 2025 | 381 | 0.080 |
Why?
|
| Algorithms | 1 | 2015 | 1595 | 0.080 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2008 | 97 | 0.070 |
Why?
|
| Sweden | 2 | 2017 | 33 | 0.070 |
Why?
|
| Neuropsychological Tests | 2 | 2022 | 923 | 0.070 |
Why?
|
| Methylphenidate | 1 | 2007 | 55 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2012 | 654 | 0.070 |
Why?
|
| Neurologic Examination | 1 | 2007 | 192 | 0.070 |
Why?
|
| Genome-Wide Association Study | 3 | 2019 | 1642 | 0.070 |
Why?
|
| Craniofacial Abnormalities | 1 | 2008 | 244 | 0.070 |
Why?
|
| Central Nervous System Stimulants | 1 | 2007 | 125 | 0.070 |
Why?
|
| Interviews as Topic | 2 | 2018 | 369 | 0.070 |
Why?
|
| Logistic Models | 3 | 2018 | 1795 | 0.070 |
Why?
|
| Cognition | 2 | 2022 | 736 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 2048 | 0.070 |
Why?
|
| Risk | 2 | 2019 | 750 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2021 | 1245 | 0.060 |
Why?
|
| Autoimmunity | 2 | 2022 | 172 | 0.060 |
Why?
|
| DNA Mutational Analysis | 2 | 2021 | 793 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 3358 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 3657 | 0.060 |
Why?
|
| Phosphatidylethanolamines | 1 | 2025 | 22 | 0.060 |
Why?
|
| Ubiquinone | 1 | 2005 | 24 | 0.060 |
Why?
|
| Phosphatidylcholines | 1 | 2025 | 41 | 0.060 |
Why?
|
| Cerebral Infarction | 1 | 2005 | 43 | 0.060 |
Why?
|
| Ethanolamine | 1 | 2024 | 8 | 0.060 |
Why?
|
| Parents | 2 | 2024 | 1020 | 0.060 |
Why?
|
| Consciousness Disorders | 1 | 2004 | 23 | 0.060 |
Why?
|
| Cerebral Ventricles | 1 | 2005 | 80 | 0.060 |
Why?
|
| Qualitative Research | 2 | 2018 | 521 | 0.060 |
Why?
|
| Mutism | 1 | 2004 | 29 | 0.060 |
Why?
|
| Choline | 1 | 2024 | 55 | 0.060 |
Why?
|
| Dairy Products | 1 | 2024 | 44 | 0.060 |
Why?
|
| Receptors, Virus | 1 | 2024 | 104 | 0.060 |
Why?
|
| Neuroimaging | 2 | 2017 | 332 | 0.060 |
Why?
|
| Qb-SNARE Proteins | 1 | 2023 | 6 | 0.060 |
Why?
|
| Age Factors | 3 | 2021 | 2801 | 0.060 |
Why?
|
| Influenza A virus | 1 | 2004 | 134 | 0.060 |
Why?
|
| DNA Copy Number Variations | 2 | 2021 | 940 | 0.060 |
Why?
|
| Cations | 1 | 2023 | 37 | 0.060 |
Why?
|
| Muscle, Skeletal | 3 | 2021 | 939 | 0.060 |
Why?
|
| Mevalonic Acid | 1 | 2023 | 18 | 0.050 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2023 | 27 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 111 | 0.050 |
Why?
|
| Prognosis | 1 | 2012 | 4490 | 0.050 |
Why?
|
| Collagen Type VI | 1 | 2022 | 4 | 0.050 |
Why?
|
| Azathioprine | 1 | 2022 | 54 | 0.050 |
Why?
|
| Muscle Spasticity | 1 | 2023 | 70 | 0.050 |
Why?
|
| Oxidoreductases | 1 | 2023 | 92 | 0.050 |
Why?
|
| Memory and Learning Tests | 1 | 2022 | 7 | 0.050 |
Why?
|
| Fruit | 1 | 2024 | 221 | 0.050 |
Why?
|
| Oligodendroglia | 1 | 2023 | 84 | 0.050 |
Why?
|
| Guanosine | 1 | 2022 | 11 | 0.050 |
Why?
|
| Antibodies | 1 | 2024 | 370 | 0.050 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2017 | 119 | 0.050 |
Why?
|
| Amphotericin B | 1 | 2022 | 90 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 239 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 172 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2017 | 771 | 0.050 |
Why?
|
| Exons | 2 | 2016 | 795 | 0.050 |
Why?
|
| Cyclic GMP | 1 | 2022 | 92 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2023 | 243 | 0.050 |
Why?
|
| Lipids | 1 | 2025 | 513 | 0.050 |
Why?
|
| Drosophila melanogaster | 2 | 2017 | 738 | 0.050 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2022 | 82 | 0.050 |
Why?
|
| Animals | 5 | 2024 | 33692 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2008 | 826 | 0.050 |
Why?
|
| Observer Variation | 2 | 2015 | 302 | 0.050 |
Why?
|
| Pyridostigmine Bromide | 1 | 2021 | 13 | 0.050 |
Why?
|
| Internationality | 1 | 2022 | 130 | 0.050 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2021 | 18 | 0.050 |
Why?
|
| Long Term Adverse Effects | 1 | 2021 | 12 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 1845 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 393 | 0.050 |
Why?
|
| Agammaglobulinemia | 1 | 2021 | 39 | 0.050 |
Why?
|
| Sex Factors | 1 | 2024 | 1254 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 114 | 0.050 |
Why?
|
| Facies | 1 | 2021 | 155 | 0.050 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2021 | 76 | 0.050 |
Why?
|
| Symptom Assessment | 1 | 2021 | 98 | 0.050 |
Why?
|
| Nephrotic Syndrome | 1 | 2021 | 47 | 0.050 |
Why?
|
| Inheritance Patterns | 1 | 2021 | 125 | 0.050 |
Why?
|
| Base Sequence | 2 | 2016 | 3093 | 0.040 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 49 | 0.040 |
Why?
|
| Time Factors | 2 | 2021 | 6198 | 0.040 |
Why?
|
| Cerebral Angiography | 1 | 2000 | 101 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2015 | 1166 | 0.040 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2021 | 90 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2016 | 3871 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2022 | 293 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2022 | 571 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 285 | 0.040 |
Why?
|
| Gene Deletion | 2 | 2016 | 793 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2020 | 190 | 0.040 |
Why?
|
| HLA-A3 Antigen | 1 | 2019 | 1 | 0.040 |
Why?
|
| HLA-B7 Antigen | 1 | 2019 | 2 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 203 | 0.040 |
Why?
|
| Mathematical Concepts | 1 | 2018 | 7 | 0.040 |
Why?
|
| Electroencephalography | 1 | 2004 | 861 | 0.040 |
Why?
|
| California | 1 | 2019 | 128 | 0.040 |
Why?
|
| Organizational Innovation | 1 | 2018 | 44 | 0.040 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2020 | 199 | 0.040 |
Why?
|
| Punctures | 1 | 2018 | 55 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 267 | 0.040 |
Why?
|
| Influenza, Human | 1 | 2004 | 648 | 0.040 |
Why?
|
| Reading | 1 | 2018 | 77 | 0.040 |
Why?
|
| Family Relations | 1 | 2018 | 69 | 0.040 |
Why?
|
| Registries | 1 | 2024 | 1382 | 0.040 |
Why?
|
| Water Quality | 1 | 2017 | 7 | 0.040 |
Why?
|
| Geography, Medical | 1 | 2017 | 16 | 0.040 |
Why?
|
| Lymphoma | 1 | 2021 | 321 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 1303 | 0.040 |
Why?
|
| Haplotypes | 1 | 2019 | 519 | 0.040 |
Why?
|
| Diet Surveys | 1 | 2017 | 98 | 0.040 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2017 | 83 | 0.030 |
Why?
|
| Air Pollution | 1 | 2017 | 67 | 0.030 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2016 | 67 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 353 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2018 | 449 | 0.030 |
Why?
|
| Focus Groups | 1 | 2017 | 200 | 0.030 |
Why?
|
| Mice | 2 | 2024 | 17468 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2017 | 316 | 0.030 |
Why?
|
| Binding Sites | 1 | 2019 | 1292 | 0.030 |
Why?
|
| Optic Atrophy | 1 | 2016 | 47 | 0.030 |
Why?
|
| Arabs | 1 | 2016 | 28 | 0.030 |
Why?
|
| Point Mutation | 1 | 2017 | 347 | 0.030 |
Why?
|
| Muscles | 1 | 2016 | 288 | 0.030 |
Why?
|
| Golgi Apparatus | 1 | 2016 | 92 | 0.030 |
Why?
|
| Vegetables | 1 | 2017 | 261 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 266 | 0.030 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2016 | 121 | 0.030 |
Why?
|
| Herpesvirus 1, Human | 1 | 2014 | 26 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2021 | 1478 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 1417 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2018 | 547 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 1166 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1399 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2015 | 168 | 0.030 |
Why?
|
| Dystroglycans | 1 | 2013 | 4 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 263 | 0.030 |
Why?
|
| Goals | 1 | 2014 | 130 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2017 | 527 | 0.030 |
Why?
|
| Glycosylation | 1 | 2013 | 113 | 0.030 |
Why?
|
| Caenorhabditis elegans | 1 | 2014 | 223 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 431 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1684 | 0.030 |
Why?
|
| Pedigree | 1 | 2016 | 1582 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 753 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 2533 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2016 | 877 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2014 | 1083 | 0.020 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2011 | 23 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2017 | 995 | 0.020 |
Why?
|
| Muscle Strength | 1 | 2011 | 75 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2014 | 678 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2012 | 757 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 2698 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2012 | 574 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2011 | 256 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 288 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 730 | 0.020 |
Why?
|
| Asthma | 1 | 2017 | 746 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 3325 | 0.020 |
Why?
|
| Smoking | 1 | 2014 | 1032 | 0.020 |
Why?
|
| Creatine | 1 | 2008 | 41 | 0.020 |
Why?
|
| Sample Size | 1 | 2008 | 85 | 0.020 |
Why?
|
| Optic Neuritis | 1 | 2008 | 28 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2848 | 0.020 |
Why?
|
| Gadolinium | 1 | 2008 | 103 | 0.020 |
Why?
|
| Serologic Tests | 1 | 2008 | 119 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 810 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1684 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 1585 | 0.020 |
Why?
|
| Aged | 2 | 2019 | 19033 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2008 | 358 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 4507 | 0.020 |
Why?
|
| Neurons | 1 | 2016 | 1926 | 0.020 |
Why?
|
| Middle Aged | 2 | 2020 | 25929 | 0.020 |
Why?
|
| Schizophrenia | 1 | 2008 | 299 | 0.020 |
Why?
|
| Coenzymes | 1 | 2005 | 12 | 0.020 |
Why?
|
| Contrast Media | 1 | 2008 | 469 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 2005 | 54 | 0.020 |
Why?
|
| Electron Transport | 1 | 2005 | 54 | 0.020 |
Why?
|
| Mitochondria, Muscle | 1 | 2005 | 34 | 0.020 |
Why?
|
| Nasal Lavage Fluid | 1 | 2004 | 14 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2005 | 140 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2005 | 183 | 0.010 |
Why?
|
| Texas | 1 | 2004 | 3542 | 0.010 |
Why?
|